Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UTP3 small subunit processome component, also known as Sas10 or CRLZ1, is a highly conserved nucleolar RNA-binding protein critical for the biogenesis of the eukaryotic ribosomal small subunit. It is a core component of the small subunit (SSU) processome, ensuring proper maturation of 18S rRNA and coordinating the assembly and nucleolar localization of other SSU processome members such as MPP10, UTP12, UTP13, UTP25, and EMG1[1][2][3]. UTP3 also recruits the RNA exosome enzyme EXOSC10 to the nucleolus, facilitating the processing and degradation of pre-rRNA intermediates[2]. Beyond ribosome biogenesis, UTP3 has roles in gene silencing through chromatin structure regulation[3] and has been linked to cancer chemoresistance via regulation of apoptosis through interaction with the transcription factor c-Myc[1]. Mutations or dysregulation of UTP3 have been associated with a subset of genetic disorders and cancer phenotypes, but it is not currently classified as a therapeutic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UTP3 small subunit processome component (UTP3).